Fredun Pharmaceuticals Limited Announces Allotment of Bonus Equity Shares
Fredun Pharmaceuticals Limited has announced the allotment of 11,025,380 fully paid-up bonus equity shares. The Board of Directors approved the issuance during a meeting held on July 17, 2026.The bonus issue was distributed in a 2:1 ratio, providing shareholders with 2 new bonus equity shares for every 1 existing equity share held as of the record date on July 16, 2026. Each of these new shares carries a face value of ₹ 10.
Impact on Share Capital
The issuance has resulted in a significant increase in the company's paid-up share capital. The updated figures are detailed in the table below:| Particulars | No. of Shares | Face Value (Rs.) | Amount in Rs. |
|---|---|---|---|
| Paid-up share capital (Pre-Bonus Issue) | 55,12,690 | 10 | 5,51,26,900 |
| Paid-up share capital (Post-Bonus Issue) | 1,65,38,070 | 10 | 16,53,80,700 |
The newly allotted bonus equity shares will rank pari-passu with existing equity shares in all respects. This includes the entitlement to dividends and other corporate benefits declared by the company following the allotment.
Stock Price Movement
As of 13:05, Fredun Pharmaceuticals Ltd shares are sliding to ₹953.90, down 4.01%. The stock is currently navigating a wide intraday swing between its low of ₹943.00 and a high of ₹999.00.Disclaimer: Due care and diligence have been taken in compiling and presenting news and market-related content. However, errors or omissions may arise despite such efforts.
The information provided is for general informational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any securities. Readers are advised to rely on their own assessment and judgment and consult appropriate financial advisers, if required, before taking any investment-related decisions.
Any views, opinions, or statements expressed, where applicable, are those of the respective analysts or experts and do not reflect the views of this website. The website has no association with such viewpoints and does not assume any responsibility for them.